This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Victoria P. Werth, MD

Arch Dermatol. 1996;132(12):1435-1439.

Abstract
Objective
To determine if intravenous high-dose "pulse" glucocorticoid therapy induced remission or reduced subsequent requirements for orally administered glucocorticoids in pemphigus vulgaris.

Design
Retrospective, case-controlled study.

Setting
Academic referral center.

Patients or Other Participants
Fifteen patients, all of whom had pemphigus vulgaris, were included in the analysis. The group comprised all patients with pemphigus vulgaris seen during 11.5 years who did not initially respond to low doses (<40 mg/d) of prednisone and who were followed up for at least 500 days after beginning treatment.

Interventions
One group received very high-dose intravenous pulse(s) of methylprednisolone sodium succinate (Solu-Medrol) (n=9). The other group did not receive intravenous pulse therapy (n=6).

Main Outcome Measures
Glucocorticoid dose and status of disease.

Results
Patients treated with pulse therapy and control patients treated with conventional oral prednisone had similar initial disease severity. Six of the 9 patients who received pulse therapy showed improvement of their pemphigus vulgaris, and 4 of the 9 had discontinued all glucocorticoids and were in remission at mean (±SEM) 269±27 days. They have continued in remission without receiving prednisone for a mean of 714± 142 days. Therapeutic benefit was seen in patients who received pulse therapy early or late after beginning glucocorticoid therapy. In contrast, none of the 6 control patients has achieved long-term remissions without therapy. All of the controls have had long courses of glucocorticoid therapy, with a mean of 1467±112 days of prednisone treatment. Overall, the mean (±SEM) prednisone dose between days 350 and 500 from onset of glucocorticoid therapy was 9.2±4.2 mg/d for those who received pulse therapy vs 21.0±3.3 mg/d (P2<.05) for those who did not (unpaired 2-tailed t test).

Conclusions
High-dose pulse administration of glucocorticoids is a potentially effective therapy to be considered in the treatment of patients with severe pemphigus vulgaris. Similar patients treated with conventional orally administered doses of prednisone had protracted courses requiring years of glucocorticoid therapy with no long-term remissions.

Arch Dermatol. 1996;132:1435-1439

Author Affiliations
From the Department of Dermatology, University of Pennsylvania, and the Philadelphia Veterans Administration Hospital, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus.
Beissert et al.
Arch Dermatol 2006;142:1447-1454.
ABSTRACT | FULL TEXT  

Randomized Controlled Trial of Adjuvant Oral Dexamethasone Pulse Therapy in Pemphigus Vulgaris: PEMPULS Trial
Mentink et al.
Arch Dermatol 2006;142:570-576.
ABSTRACT | FULL TEXT  

Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma
Kreuter et al.
Arch Dermatol 2005;141:847-852.
ABSTRACT | FULL TEXT  

Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists
Nguyen et al.
Arch Dermatol 2004;140:327-334.
ABSTRACT | FULL TEXT  

Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes
Nguyen et al.
J. Biol. Chem. 2004;279:2135-2146.
ABSTRACT | FULL TEXT  

Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases
Ahmed and Dahl
Arch Dermatol 2003;139:1051-1059.
ABSTRACT | FULL TEXT  

PEMPHIGUS VULGARIS: UPDATE ON ETIOPATHOGENESIS, ORAL MANIFESTATIONS, AND MANAGEMENT
Scully and Challacombe
CROBM 2002;13:397-408.
ABSTRACT | FULL TEXT  

Pulse Intravenous Cyclophosphamide Therapy in Pemphigus
Fleischli et al.
Arch Dermatol 1999;135:57-61.
ABSTRACT | FULL TEXT  

Therapy of Pemphigus Vulgaris
Stanley
Arch Dermatol 1999;135:76-78.
FULL TEXT  

The Pathophysiological Significance of Nondesmoglein Targets of Pemphigus Autoimmunity: Development of Antibodies Against Keratinocyte Cholinergic Receptors in Patients With Pemphigus Vulgaris and Pemphigus Foliaceus
Nguyen et al.
Arch Dermatol 1998;134:971-980.
ABSTRACT | FULL TEXT  

Reliability Testing of the Dermatology Index of Disease Severity (DIDS) An Index for Staging the Severity of Cutaneous Inflammatory Disease
Faust et al.
Arch Dermatol 1997;133:1443-1448.
ABSTRACT  

Pulse Glucocorticoid Therapy: The 'Big Shot' Revisited
Roujeau
Arch Dermatol 1996;132:1499-1502.
ABSTRACT